IL-19 blockade

IL-19 blockade refers to the therapeutic strategy of neutralizing the cytokine Interleukin-19 (IL-19) to treat glioblastoma multiforme (GBM) and other conditions characterized by an immunosuppressive microenvironment. In GBM, IL-19 is identified as a key immune-suppressive cytokine prevalent in the peritumoral region and is associated with poor patient survival. Research, notably from Taipei Medical University, has shown that blocking IL-19 disrupts the IL-19-WISP1-AKT signaling axis, which inhibits the invasion of chemo-resistant GBM cells and enhances CD8+ T cell activation. This blockade reprograms the tumor microenvironment by shifting tumor-associated macrophages from pro-tumoral to anti-tumoral phenotypes, thereby overcoming resistance to standard therapies like temozolomide (TMZ).

Other names

IL-19 inhibitionIL19 inhibitionIL 19 inhibitionIL-19 neutralizationIL19 neutralizationIL 19 neutralizationanti-IL-19anti-IL19anti-IL 19